People did not choose Bakiyev and we are not going to recognize his rule

People did not choose Bakiyev and we are not going to recognize his rule.”"The authorities will realize soon that they will have to go,” Atambayev said. See the Companies’ SECfilings, and in particular, the risk factors described in their Annual Reportson Form 10-K and their most recent report on Form 10-Q. The Companies do notundertake any obligation to update these forward-looking statements.SOURCESigma-AldrichSarah Bruno of Sigma-Aldrich, +1-314-286-7810, ; orElizabeth Wolffe, Ph.D of Sangamo, +1-510-970-6000, ext. 271,; or Toranj Marphetia of Medical College of Wisconsin inMilwaukee, +1-414-456-4744, ; or Roland Buelow, Ph.D.

of OpenMonoclonal Technology, +1-650-224-6835, . NORTHBROOK, Ill., July 23 /PRNewswire/ — Underwriters Laboratories (UL) isnotifying consumers that the “Airspan” Ethernet Adaptor, identified below,bears an unauthorized UL Mark for the United States and Canada. This producthas not been evaluated by UL to the appropriate standard for safety and is notauthorized to bear the UL Mark It is unknown if this product complies withU.S. UL evaluates more than 19,000 types of products,components, materials and systems annually with 20 billion UL Marks appearingon 72,000 manufacturers’ products each year. Cautionary Statement: This release contains forward-looking statementsrelating to future performance, goals, strategic actions and initiatives andsimilar intentions and beliefs and other statements regarding Sigma-Aldrich’sand Sangamo’s expectations, goals, beliefs, intentions and the like, whichinvolve assumptions regarding the Companies’ operations and conditions in themarkets the Companies serve.

Jane Evans-Ryan +1-408-489-6391,, for Luminescent Technologies, Inc.. The rat is a widelyused laboratory animal with a well characterized immune system, a nearlycomplete genome sequence, and established transgenesis and hybridomatechnologies.OMT’s antibody platform is the result of an improvedunderstanding of B-cell development and a novel approach to the inactivationof endogenous antibody expression. A major national research center and academicmedical center, its faculty physicians and scientists direct or collaborate onmore than 3,000 research studies, publish over 1,300 peer-reviewed scientificpapers, andprovide care in virtually every specialty of medicine toapproximately 350,000 patients annually.For more information on ourtransgenic services offering, see http:// About Open Monoclonal Technology, Inc.: Open Monoclonal Technology, Inc.(“OMT”) is a private biotechnology company developing a new, fully humanmonoclonal antibody platform based on transgenic rats. The Company has customers in lifescience companies, university and government institutions, hospitals, and inindustry. Over one million scientists and technologists use its products.Sigma-Aldrich operates in 38 countries and has 7,800 employees providingexcellent service worldwide.